| |
Established
in 1995 as a spin out from Oxford University, Oxford
BioMedica is an international biotechnology company
with a diverse portfolio of products and technology,
specialising in gene-based products and technology in
the areas of cancer, neurological disease, cardiovascular
disease and blood disorders. This is underpinned by
over 70 patent families, about quarter of which are
issued. Oxford BioMedica plc was floated on the Alternative
Investment Market of the London Stock Exchange in December
1996, and was promoted to the United Kingdom Listing
Authority Official List in April 2001 following a successful
£35.5 million fund-raising.
Oxford
BioMedica is headquartered in Oxford, UK and has a wholly-owned
subsidiary in San Diego, USA
Currently
Oxford BioMedica has corporate collaborations with Aventis,
IDM, Amersham, Valentis, Virbac and Wyeth. BioMedica
has two products in Phase I/II clinical trials: MetXia®
for late-stage breast cancer, and TroVax®
for late-stage colorectal cancer. |
